Close Menu

NEW YORK – CareDx said on Tuesday that it has formed an exclusive partnership with Weill Cornell Medicine to develop and commercialize UroMap, a urine-based gene expression test for acute cellular rejection in kidney transplant recipients.

The company said it is collaborating with Weill Cornell on a multiyear research collaboration with exclusive rights to bring UroMap to patients. CareDx obtained the exclusive rights to the UroMap technology through a license agreement with Cornell University. Specific financial terms of the deal were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Lancet has made changes to its peer-review process in response to its recent retraction of a COVID-19-related paper, Science reports.

The New York Times reports that a series of emails show how Department of Health and Human Services officials sought to silence the Centers for Disease Control and Prevention.

A new initiative aims to move Australia's genome sequencing labs onto one system, the Sydney Morning Herald reports.

In PLOS this week: recessive mutation tied to early-onset dilated cardiomyopathy, epigenetic analysis of lung adenocarcinoma, and more.